Bolt Biotherapeutics Inc BOLT

$6.30 -0.13 (-2.02%)

Valuation

Market cap
12,598,000
Revenue TTM
$7,700,000
Net income TTM
$-33,380,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-433.51%
Debt to equity
0.00

Trading

Volume
111,865
Avg volume
313,368
Day's range
$6.16 – $6.66
Shares out
1,926,000
Stochastic %K
52%
Beta
0.85
Analysts
Moderate Buy
Price target
$11.33

Price

Company profile

Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-30...

Show more

Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 665 9295
Website
https://www.boltbio.com
Address
900 Chesapeake Drive, Redwood City, United States

Latest news

Stocktwits

StockTwitsGhost Nov 9, 7:52 PM
$CVKD deep modeling 🦜 (see attached). What's happening: On Oct 7, Cadrenal hired Tungsten Advisors to run a formal process to license, sell or partner its drugs, or merge the company. The $BOLT connection: Tungsten represented Prana, the private company that reverse-merged into Bolt on Oct 23. That deal came with a $120M PIPE at ~$8.57/share, about 2x BOLT's prior close, and BOLT jumped ~63%. Valuation: at ~$1.11, CVKD is worth ~$4M, about the ~$4.2M of cash it reported in early August. Pipeline: CAD-1005 (FDA-agreed Phase 3 design, Orphan + Fast Track), Phase 3-ready tecarfarin, frunexian, CAD-2000. Part 2 continued…
1 replies
skyrockets_Inc Nov 9, 5:58 PM
$CVKD Added more. 150k shares at 1.05/share avg. Tungsten Advisors just completed a great deal for $BOLT shareholders, and they will likely do the same here. I'm expecting news on some sort of resolution in the next 4-6 weeks, before EOY.
1 replies
skyrockets_Inc Nov 2, 4:57 PM
$CVKD Been adding here slowly over the past few weeks. 100k shares starter position right now at 1.00/share avg. Will double to 200k shares next week if stock is still around these levels. They engaged Tungsten Advisors (same as $BOLT) about a month ago to look into strategic alternatives. Most definitely going to be some sort of resolution here in the next 4-6 weeks imo.
1 replies
AlertsAndNews Nov 2, 12:22 AM
Highlights from last week... Good to see monster momentum back. ER helping, INO FDA approval was a monster, AIOK and that 3.50 div a banger and half. Options flows on GDYN on Thursday into ER quite good too. Let's do it again. Link in bio for more $INO $AIOK $SGRY $BOLT $GDYN All trading and investing involves a risk of loss. Do your own due diligence always!
1 replies
AlertsAndNews Oct 31, 5:28 PM
Highlights of the week. Some monsters in here, that AIOK div and the FDA approval on INO. Running out of room on this pic. $INO $AIOK $GMAB $GDYN $BOLT to name a few. Before the crowd! Link in bio for more. All trading and investing involves a risk of loss. Do your own due diligence always! Enjoy the rest of your weekend!
0 replies
onkelhubert Oct 28, 8:04 PM
$BOLT Concurrently and in connection with the execution of the Merger Agreement, certain officers, directors and certain stockholders of Prana as of immediately prior to the Merger, and certain of the directors and officers of the Company as of immediately prior to the Merger entered into lock-up agreements with the Company and Prana, pursuant to which each such stockholder will be subject to a 180-day lockup on the sale or transfer of shares of Common Stock and Series D Preferred Stock held by each such stockholder at the Closing, including those shares received by Prana stockholders in the Merger (the “Lock-up Agreements”). https://investors.boltbio.com/static-files/30703dff-4a2b-4681-a653-e4f29ffe2fce
0 replies
skyrockets_Inc Oct 28, 2:50 PM
$LGVN Lucid Capital as financial advisor. Most definitely a RM coming w/ asset sale or partnering. Possibly CVRs instead but I think will be a sign and close reverse merger like $BOLT $TCRT and $LSTA recently did. Easy money to be made here. Bids keep stacking. https://investors.longeveron.com/news/news-details/2026/Longeveron-Announces-Engagement-of-Lucid-Capital-Markets/default.aspx
0 replies
skyrockets_Inc Oct 27, 6:53 PM
$LGVN Position now increased to 150k shares at 1.60/share avg. Will add 50k more after 10Q if overall OS has increased so I don't break 5% threshold. There has been consistent buying the past 10 days that is mimicking the likes of $BOLT and $CYCN before they announced their mergers.....very suspicious and I like it :) Only two realistic options I see at this point..... A). Find a non-dilutive partner to advance Laromestrocel in Aging/Frailty and/or Alzheimer's or.... B). Reverse merge the shell and sell asset. At 1.60/share this thing is SUPER CHEAP IMO The reverse merger valuation theory..... If LGVN gets 10m valuation for shell and has net cash of (-5m) at closing, valuation of shell will be 5m / 3.2 OS = 1.6/share FLOOR for shell only . Add in value of laromestrocel at 5m-10m conservative and you get back to 10-15m / 3.2m or 3.2 - 4.70/share So downside risk from these levels is LOW... and upside potential of whatever drug is worth (could be multiples of current pps).
1 replies